{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:50:23Z","timestamp":1791175823203,"version":"4.1.0"},"reference-count":144,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Recent studies using massively parallel sequencing technologies, so-called next-generation sequencing, have uncovered numerous recurrent, single-gene variants or mutations across the spectrum of myeloid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To review the recent advances in the understanding of the molecular basis of myeloid neoplasms, including their significance for diagnostic and prognostic purposes and the possible implications for the development of novel therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>Literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The recurrent mutations found in myeloid malignancies fall into distinct functional categories. These include (1) cell signaling factors, (2) transcription factors, (3) regulators of the cell cycle, (4) regulators of DNA methylation, (5) regulators of histone modification, (6) RNA-splicing factors, and (7) components of the cohesin complex. As the clinical significance of these mutations and mutation combinations is established, testing for their presence is likely to become a routine part of the diagnostic workup. This review will attempt to establish a framework for understanding these mutations in the context of myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2014-0096-ra","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T08:26:41Z","timestamp":1408955201000},"page":"594-601","source":"Crossref","is-referenced-by-count":14,"title":["Molecular Genetic Biomarkers in Myeloid Malignancies"],"prefix":"10.5858","volume":"139","author":[{"given":"Anna P.","family":"Matynia","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of Utah, Salt Lake City (Drs Matynia and Kelley); and Research and Development, ARUP Laboratories, Salt Lake City, Utah (Drs Szankasi and Shen)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Szankasi","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Utah, Salt Lake City (Drs Matynia and Kelley); and Research and Development, ARUP Laboratories, Salt Lake City, Utah (Drs Szankasi and Shen)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Utah, Salt Lake City (Drs Matynia and Kelley); and Research and Development, ARUP Laboratories, Salt Lake City, Utah (Drs Szankasi and Shen)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Kelley","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Utah, Salt Lake City (Drs Matynia and Kelley); and Research and Development, ARUP Laboratories, Salt Lake City, Utah (Drs Szankasi and Shen)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2014,8,25]]},"reference":[{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b01","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","article-title":"Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis","volume":"200","author":"Tong","year":"2004","journal-title":"J Exp Med"},{"issue":"12","key":"2020081222325389800_i1543-2165-139-5-594-b02","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","article-title":"Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways","volume":"105","author":"Tong","year":"2005","journal-title":"Blood"},{"issue":"pt 16","key":"2020081222325389800_i1543-2165-139-5-594-b03","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1242\/jcs.113.16.2813","article-title":"SOCS: physiological suppressors of cytokine signaling","volume":"113","author":"Krebs","year":"2000","journal-title":"J Cell Sci"},{"issue":"7","key":"2020081222325389800_i1543-2165-139-5-594-b04","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b05","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/epi.09.33","article-title":"DNA hypomethylation in cancer cells","volume":"1","author":"Ehrlich","year":"2009","journal-title":"Epigenomics"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b06","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b07","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"issue":"23","key":"2020081222325389800_i1543-2165-139-5-594-b08","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1101\/gad.1464906","article-title":"The cancer epigenome\u2014components and functional correlates","volume":"20","author":"Ting","year":"2006","journal-title":"Genes Dev"},{"key":"2020081222325389800_i1543-2165-139-5-594-b09","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.med.59.061606.095816","article-title":"Cancer epigenetics: modifications, screening, and therapy","volume":"59","author":"Gal-Yam","year":"2008","journal-title":"Annu Rev Med"},{"key":"2020081222325389800_i1543-2165-139-5-594-b10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/1471-2164-11-519","article-title":"Genome-wide conserved consensus transcription factor binding motifs are hyper-methylated","volume":"11","author":"Choy","year":"2010","journal-title":"BMC Genomics"},{"issue":"25","key":"2020081222325389800_i1543-2165-139-5-594-b11","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"2020081222325389800_i1543-2165-139-5-594-b14","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1021\/bi400514k","article-title":"Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism","volume":"52","author":"Rendina","year":"2013","journal-title":"Biochemistry"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1042\/bj0550774","article-title":"The bases of the nucleic acids of some bacterial and animal viruses: the occurrence of 5-hydroxymethylcytosine","volume":"55","author":"Wyatt","year":"1953","journal-title":"Biochem J"},{"issue":"5929","key":"2020081222325389800_i1543-2165-139-5-594-b16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"6132","key":"2020081222325389800_i1543-2165-139-5-594-b18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"2020081222325389800_i1543-2165-139-5-594-b20","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/leu.2012.146","article-title":"EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms","volume":"26","author":"Ueda","year":"2012","journal-title":"Leukemia"},{"key":"2020081222325389800_i1543-2165-139-5-594-b21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev-genet-102108-134233","article-title":"Cohesin: its roles and mechanisms","volume":"43","author":"Nasmyth","year":"2009","journal-title":"Annu Rev Genet"},{"issue":"5835","key":"2020081222325389800_i1543-2165-139-5-594-b22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.1140649","article-title":"Postreplicative formation of cohesion is required for repair and induced by a single DNA break","volume":"317","author":"Strom","year":"2007","journal-title":"Science"},{"issue":"17","key":"2020081222325389800_i1543-2165-139-5-594-b23","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/emboj.2009.202","article-title":"The cohesin complex is required for the DNA damage-induced G2\/M checkpoint in mammalian cells","volume":"28","author":"Watrin","year":"2009","journal-title":"EMBO J"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10577-009-9022-5","article-title":"Cohesin, gene expression and development: lessons from Drosophila","volume":"17","author":"Dorsett","year":"2009","journal-title":"Chromosome Res"},{"issue":"21","key":"2020081222325389800_i1543-2165-139-5-594-b25","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1242\/dev.02064","article-title":"Effects of sister chromatid cohesion proteins on cut gene expression during wing development in Drosophila","volume":"132","author":"Dorsett","year":"2005","journal-title":"Development"},{"issue":"14","key":"2020081222325389800_i1543-2165-139-5-594-b26","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1242\/dev.002485","article-title":"Cohesin-dependent regulation of Runx genes","volume":"134","author":"Horsfield","year":"2007","journal-title":"Development"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2008.01.011","article-title":"Cohesins functionally associate with CTCF on mammalian chromosome arms","volume":"132","author":"Parelho","year":"2008","journal-title":"Cell"},{"issue":"7180","key":"2020081222325389800_i1543-2165-139-5-594-b28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nature06634","article-title":"Cohesin mediates transcriptional insulation by CCCTC-binding factor","volume":"451","author":"Wendt","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0092-8674(03)00162-4","article-title":"Chromosomal cohesin forms a ring","volume":"112","author":"Gruber","year":"2003","journal-title":"Cell"},{"issue":"10","key":"2020081222325389800_i1543-2165-139-5-594-b30","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet"},{"issue":"22","key":"2020081222325389800_i1543-2165-139-5-594-b31","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.18632\/oncotarget.749","article-title":"Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"3","author":"Chesnais","year":"2012","journal-title":"Oncotarget"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2008.377","article-title":"miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities","volume":"23","author":"Mraz","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b34","first-page":"2705","article-title":"Tumor cell senescence in cancer treatment","volume":"63","author":"Roninson","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b35","doi-asserted-by":"crossref","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"2020081222325389800_i1543-2165-139-5-594-b36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1349-7006.2006.00270.x","article-title":"Nucleophosmin: a versatile molecule associated with hematological malignancies","volume":"97","author":"Naoe","year":"2006","journal-title":"Cancer Sci"},{"issue":"9464","key":"2020081222325389800_i1543-2165-139-5-594-b37","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"2020081222325389800_i1543-2165-139-5-594-b38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2020081222325389800_i1543-2165-139-5-594-b39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2020081222325389800_i1543-2165-139-5-594-b40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.V61.5.876.876","article-title":"Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny","volume":"61","author":"Cashman","year":"1983","journal-title":"Blood"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b43","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2020081222325389800_i1543-2165-139-5-594-b45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b47","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition","volume":"22","author":"Chaligne","year":"2008","journal-title":"Leukemia"},{"issue":"25","key":"2020081222325389800_i1543-2165-139-5-594-b48","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2020081222325389800_i1543-2165-139-5-594-b49","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2020081222325389800_i1543-2165-139-5-594-b51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b52","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood-2009-06-227033","article-title":"Ubiquitination and degradation of the thrombopoietin receptor c-Mpl","volume":"115","author":"Saur","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2020081222325389800_i1543-2165-139-5-594-b53","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020081222325389800_i1543-2165-139-5-594-b54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2009.07860.x","article-title":"A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses","volume":"147","author":"Suessmuth","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b55","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.leu.2402834","article-title":"TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)","volume":"17","author":"Lorsbach","year":"2003","journal-title":"Leukemia"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b56","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b57","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b58","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"2020081222325389800_i1543-2165-139-5-594-b59","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b60","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b61","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri747","article-title":"Haematopoietic cell-fate decisions, chromatin regulation and ikaros","volume":"2","author":"Georgopoulos","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2020081222325389800_i1543-2165-139-5-594-b63","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2010.99","article-title":"Deletions of the transcription factor Ikaros in myeloproliferative neoplasms","volume":"24","author":"Jager","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b64","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2010-05-284356","article-title":"Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia","volume":"116","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2020081222325389800_i1543-2165-139-5-594-b65","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b66","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b67","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"22","key":"2020081222325389800_i1543-2165-139-5-594-b68","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1182\/blood-2012-01-406116","article-title":"Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia","volume":"119","author":"Beekman","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b69","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJM199508243330804","article-title":"Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia","volume":"333","author":"Dong","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood-2006-02-004275","article-title":"Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey","volume":"109","author":"Germeshausen","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2020081222325389800_i1543-2165-139-5-594-b71","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b72","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00062752-200401000-00009","article-title":"Clinical, genetic, and therapeutic insights into systemic mast cell disease","volume":"11","author":"Tefferi","year":"2004","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b73","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"2020081222325389800_i1543-2165-139-5-594-b74","unstructured":"Swerdlow SH, Campo E, Harris NL, et al . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;2008. World Health Organization Classification of Tumours."},{"issue":"17","key":"2020081222325389800_i1543-2165-139-5-594-b75","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b76","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"2020081222325389800_i1543-2165-139-5-594-b77","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b78","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"issue":"7367","key":"2020081222325389800_i1543-2165-139-5-594-b79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2012","journal-title":"Nat Genet"},{"issue":"22","key":"2020081222325389800_i1543-2165-139-5-594-b81","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2020081222325389800_i1543-2165-139-5-594-b82","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2020081222325389800_i1543-2165-139-5-594-b83","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2020081222325389800_i1543-2165-139-5-594-b84","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2020081222325389800_i1543-2165-139-5-594-b85","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b86","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b87","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"issue":"25","key":"2020081222325389800_i1543-2165-139-5-594-b88","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1038\/onc.2010.117","article-title":"Array-based genomic resequencing of human leukemia","volume":"29","author":"Yamashita","year":"2010","journal-title":"Oncogene"},{"issue":"7","key":"2020081222325389800_i1543-2165-139-5-594-b89","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b90","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.7","article-title":"DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia","volume":"1","author":"Ewalt","year":"2011","journal-title":"Blood Cancer J"},{"issue":"10","key":"2020081222325389800_i1543-2165-139-5-594-b91","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2020081222325389800_i1543-2165-139-5-594-b92","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b93","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/leu.2010.241","article-title":"A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders","volume":"25","author":"Yoshida","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b94","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"10","key":"2020081222325389800_i1543-2165-139-5-594-b95","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2020081222325389800_i1543-2165-139-5-594-b97","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2012-05-430876","article-title":"SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes","volume":"120","author":"Visconte","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b98","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.leukres.2012.08.015","article-title":"Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts","volume":"36","author":"Cui","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"2020081222325389800_i1543-2165-139-5-594-b99","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/leu.2010.304","article-title":"An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling","volume":"25","author":"Flach","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b100","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3324\/haematol.10869","article-title":"A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia","volume":"92","author":"Bacher","year":"2007","journal-title":"Haematologica"},{"issue":"1\u20132","key":"2020081222325389800_i1543-2165-139-5-594-b101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2009.11.025","article-title":"Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia","volume":"184","author":"Qian","year":"2010","journal-title":"Chem Biol Interact"},{"issue":"25","key":"2020081222325389800_i1543-2165-139-5-594-b102","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b103","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"26","key":"2020081222325389800_i1543-2165-139-5-594-b104","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","article-title":"ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category","volume":"118","author":"Metzeler","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"14","key":"2020081222325389800_i1543-2165-139-5-594-b106","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020081222325389800_i1543-2165-139-5-594-b107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/ng.788","article-title":"Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia","volume":"43","author":"Yan","year":"2011","journal-title":"Nat Genet"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b108","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2010.247","article-title":"PHF6 mutations in adult acute myeloid leukemia","volume":"25","author":"Van Vlierberghe","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b109","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/leu.2013.236","article-title":"Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia","volume":"28","author":"Hou","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2020081222325389800_i1543-2165-139-5-594-b111","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b112","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b113","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2020081222325389800_i1543-2165-139-5-594-b114","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b115","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b116","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"24","key":"2020081222325389800_i1543-2165-139-5-594-b117","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","article-title":"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia","volume":"119","author":"Ribeiro","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2020081222325389800_i1543-2165-139-5-594-b118","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2011.39.2092","article-title":"Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia","volume":"30","author":"Marcucci","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b119","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/leu.2011.382","article-title":"Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association","volume":"26","author":"Renneville","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/blood-2011-07-369934","article-title":"DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications","volume":"119","author":"Hou","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2020081222325389800_i1543-2165-139-5-594-b121","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia","volume":"118","author":"Shen","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2020081222325389800_i1543-2165-139-5-594-b122","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","article-title":"Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia","volume":"29","author":"Thol","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b123","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"2020081222325389800_i1543-2165-139-5-594-b124","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2020081222325389800_i1543-2165-139-5-594-b125","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020081222325389800_i1543-2165-139-5-594-b126","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1200\/JCO.2010.28.2285","article-title":"Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group","volume":"28","author":"Boissel","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/85820","article-title":"Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBPalpha), in acute myeloid leukemia","volume":"27","author":"Pabst","year":"2001","journal-title":"Nat Genet"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.leukres.2010.09.018","article-title":"Combined testing for CCAAT\/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features","volume":"35","author":"Szankasi","year":"2011","journal-title":"Leuk Res"},{"issue":"18","key":"2020081222325389800_i1543-2165-139-5-594-b129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"2020081222325389800_i1543-2165-139-5-594-b130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b131","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.leu.2404188","article-title":"Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)","volume":"20","author":"Boissel","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"2020081222325389800_i1543-2165-139-5-594-b132","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"Dohner","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2020081222325389800_i1543-2165-139-5-594-b133","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2020081222325389800_i1543-2165-139-5-594-b134","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2010.124","article-title":"Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML","volume":"24","author":"Dicker","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2020081222325389800_i1543-2165-139-5-594-b135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergencyto.2009.02.018","article-title":"Association of MLL amplification with poor outcome in acute myeloid leukemia","volume":"192","author":"Maitta","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2020081222325389800_i1543-2165-139-5-594-b136","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cancergencyto.2009.05.008","article-title":"A partial nontandem duplication of the MLL gene in four patients with acute myeloid leukemia","volume":"195","author":"Sarova","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2020081222325389800_i1543-2165-139-5-594-b137","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1073\/pnas.1019625108","article-title":"C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice","volume":"108","author":"Wang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2020081222325389800_i1543-2165-139-5-594-b138","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"14","key":"2020081222325389800_i1543-2165-139-5-594-b139","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation","volume":"115","author":"Chou","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2020081222325389800_i1543-2165-139-5-594-b140","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","article-title":"IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status","volume":"116","author":"Schnittger","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b141","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/leu.2011.142","article-title":"Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups","volume":"25","author":"Damm","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"2020081222325389800_i1543-2165-139-5-594-b142","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/sj.leu.2404389","article-title":"Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications","volume":"20","author":"Nyvold","year":"2006","journal-title":"Leukemia"},{"issue":"16","key":"2020081222325389800_i1543-2165-139-5-594-b143","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","volume":"122","author":"Chaturvedi","year":"2013","journal-title":"Blood"},{"key":"2020081222325389800_i1543-2165-139-5-594-b144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523035","article-title":"TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo","author":"Ma","year":"2014]","journal-title":"Blood"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/5\/594\/1613897\/arpa_2014-0096-ra.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/5\/594\/1613897\/arpa_2014-0096-ra.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:34:29Z","timestamp":1764790469000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/5\/article-p594.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,25]]},"references-count":144,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,8,25]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2014-0096-ra","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8,25]]}}}